Capital Research Global Investors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,139,043
| Closed | -$85M | – | 442 |
|
|
2025
Q2 | $85M | Sell |
1,139,043
-438,280
| -28% | -$29M | 0.02% | 301 |
|
|
2025
Q1 | $100M | Sell |
1,577,323
-2,661,631
| -63% | -$181M | 0.02% | 287 |
|
|
2024
Q4 | $331M | Sell |
4,238,954
-203,699
| -5% | -$16.4M | 0.07% | 171 |
|
|
2024
Q3 | $357M | Sell |
4,442,653
-2,472,556
| -36% | -$200M | 0.07% | 156 |
|
|
2024
Q2 | $572M | Buy |
6,915,209
+240,458
| +4% | +$21.2M | 0.13% | 135 |
|
|
2024
Q1 | $570M | Buy |
6,674,751
+151,183
| +2% | +$11.9M | 0.13% | 138 |
|
|
2023
Q4 | $558M | Sell |
6,523,568
-99,580
| -2% | -$8.61M | 0.14% | 145 |
|
|
2023
Q3 | $593M | Sell |
6,623,148
-66,391
| -1% | -$5.93M | 0.16% | 125 |
|
|
2023
Q2 | $570M | Buy |
6,689,539
+35,797
| +0.5% | +$3.03M | 0.15% | 133 |
|
|
2023
Q1 | $551M | Buy |
6,653,742
+697,678
| +12% | +$56.5M | 0.16% | 130 |
|
|
2022
Q4 | $468M | Sell |
5,956,064
-330,212
| -5% | -$26.5M | 0.14% | 140 |
|
|
2022
Q3 | $465M | Buy |
6,286,276
+4,840
| +0.1% | +$348K | 0.15% | 136 |
|
|
2022
Q2 | $409M | Buy |
6,281,436
+829,430
| +15% | +$49.1M | 0.13% | 147 |
|
|
2022
Q1 | $345M | Buy |
5,452,006
+3,402,873
| +166% | +$185M | 0.09% | 184 |
|
|
2021
Q4 | $109M | Buy |
2,049,133
+915,385
| +81% | +$55.8M | 0.02% | 312 |
|
|
2021
Q3 | $80M | Sell |
1,133,748
-1,545,588
| -58% | -$97.5M | 0.02% | 328 |
|
|
2021
Q2 | $179M | Sell |
2,679,336
-3,538,162
| -57% | -$250M | 0.04% | 257 |
|
|
2021
Q1 | $690M | Buy |
6,217,498
+579,763
| +10% | +$71.7M | 0.17% | 132 |
|
|
2020
Q4 | $669M | Buy |
5,637,735
+812,220
| +17% | +$87.4M | 0.17% | 130 |
|
|
2020
Q3 | $421M | Buy |
4,825,515
+837,512
| +21% | +$73.2M | 0.13% | 155 |
|
|
2020
Q2 | $357M | Buy |
3,988,003
+1,094,203
| +38% | +$111M | 0.11% | 154 |
|
|
2020
Q1 | $288M | Buy |
2,893,800
+199,000
| +7% | +$21.6M | 0.11% | 151 |
|
|
2019
Q4 | $310M | Buy |
2,694,800
+143,800
| +6% | +$17.4M | 0.09% | 178 |
|
|
2019
Q3 | $322M | Hold |
2,551,000
| – | – | 0.11% | 167 |
|
|
2019
Q2 | $307M | Buy |
2,551,000
+1,138,850
| +81% | +$112M | 0.1% | 168 |
|
|
2019
Q1 | $124M | Hold |
1,412,150
| – | – | 0.04% | 245 |
|
|
2018
Q4 | $141M | Sell |
1,412,150
-211,850
| -13% | -$22.3M | 0.05% | 231 |
|
|
2018
Q3 | $186M | Hold |
1,624,000
| – | – | 0.05% | 238 |
|
|
2018
Q2 | $146M | Buy |
1,624,000
+400,000
| +33% | +$33.8M | 0.04% | 266 |
|
|
2018
Q1 | $89.5M | Buy |
1,224,000
+870,541
| +246% | +$59.7M | 0.03% | 302 |
|
|
2017
Q4 | $20.5M | Buy |
+353,459
| New | +$18.6M | 0.01% | 374 |
|
Other funds holding HAE
RRAM
Capital Research Global Investors's HAE Position: Q3 2025 in Review
Capital Research Global Investors sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 1,139,043 shares — an estimated $85M sold.
Capital Research Global Investors first reported a position in HAE in Q4 2017 and held it in 31 quarters. The position peaked at $690M in Q1 2021. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.
- Capital Research Global Investors reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
- Capital Research Global Investors sold 1,139,043 Haemonetics shares in Q3 2025, an estimated $85M.
- Capital Research Global Investors first reported a position in Haemonetics in Q4 2017 and held it in 31 quarters.
- Capital Research Global Investors's Haemonetics position peaked at $690M in Q1 2021.
- 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.
Based on Capital Research Global Investors's 13F filing for Q3 2025, filed 13 Nov 2025.